MYC-Rearrangement Affects Prognosis 2 Years Post-DLBCL Diagnosis

News
Article

MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.

Patients with diffuse large B-cell lymphoma (DLBCL) and MYC-rearrangement may be most at risk for negative outcomes when the disease is MYC double hit/triple-hit and when MYC is translocated to an immunoglobulin (IG) partner, according to a study published in the Journal of Clinical Oncology.

Andreas Rosenwald, MD, of University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany, and colleagues conducted this study to examine if the impact of MYC rearrangement on prognosis was influenced by the MYC partner gene (IG or a non-IG gene).

“The routine work-up of aggressive B-cell non-Hodgkin lymphoma at many institutions now includes FISH testing for MYC-rearrangement and, if positive, for BCL2 and BCL6 loci,” they wrote.

However, many questions about the role of MYC rearrangement remain.

The study looked at 5,117 patients with DLBCL taken from large prospective trials and patient registries in Europe and North America. All patients were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, or a similar treatment regimen.

Of the included patients, 47% had biopsy material sufficient for assessment of MYC-rearrangement. Among those patients, 11% had MYC-rearrangement, and this rearrangement was associated with significantly shorter progression-free survival (PFS) and overall survival (OS).

The researchers noted a time-dependent effect on outcome for patients with MYC-rearrangement, with the strongest effect occurring within the first 2 years after diagnosis; beyond the first 2 years, the negative effect of MYC- rearrangement was not noted.

“Thus, the survival probability of patients with MYC-rearrangement DLBCL who survived for at least 2 years did not differ from those with DLBCL without MYC-rearrangement,” the researchers wrote.

The adverse effect of MYC-rearrangement was only found in patients with a concurrent rearrangement of BCL2 and/or BCL6 and an IG partner (HR=2.4; 95% CI, 1.6–3.6; P<.001). This effect was most evident in the first 2 years after diagnosis (PFS: HR=2.9; 95% CI, 2.0–4.3 and OS:HR=3.6; 95% CI, 2.5–5.4).

This finding may have two significant implications, according to the researchers.

“First, future FISH strategies in DLBCL may have to include the IG lightchain loci in cases where MYC is rearranged, and second, risk-adjusted therapeutic approaches in DLBCL may be needed only for MYC-DH/TH cases in which MYC is rearranged to an IG partner,” they wrote.

In addition, because these negative effects seem to be limited to the first 2 years after diagnosis, the researchers recommended that “emphasis should be given to optimizing first-line treatment and consolidation after complete remission.”

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Related Content